World’s largest autism genome databank adds more than 2,000 sequences

November 3, 2017

The Autism Speaks MSSNG team announced the upload of an additional 2,030 fully sequenced genomes to the project’s cloud-based databank – making it the world’s largest whole genome resource for autism research. The MSSNG team includes Dr. Stephen Scherer and the Hospital for Sick Children (SickKids) in Toronto, Autism Speaks and Verily (formerly Google Life Sciences).

Read More

New test for BRCA1 and BRCA2 mutations could reduce pre-emptive mastectomies

October 25, 2017

A genetic test that more accurately predicts the risk of developing breast cancer could soon be used on high-risk groups. Researchers behind the test, available in England only at this time, say it could reduce the number of women choosing pre-emptive mastectomy surgery. The blood test looks at 18 genetic variations, or single-nucleotide polymorphisms (SNPs), known to affect the chances of getting breast cancer.

Read More

GA4GH to collaborate with 15 international genomic medicine initiatives

October 23, 2017

Advances in precision medicine depend on the ability to share genomic information voluntarily, securely and responsibly. To achieve this, The Global Alliance for Genomics and Health (GA4GH) has struck formal collaborations with 15 international genomic data initiatives. Ontario and Canada lead or help drive at least three of these, CanDIG, ICGC-ARGO and Matchmaker Exchange. Genome Canada has also announced new operational funding for the GA4GH.

Read More

Gene silencing drug opens new era for rare genetic disease treatments

October 11, 2017

Alnylam Pharmaceuticals Inc. unveiled positive results from a late-stage clinical trial of the drug patisiran for the treatment of familial amyloidotic polyneuropathy. Patisiran works by interrupting the production of a specific disease-causing protein through a process called RNA interference (RNAi), which eliminates unwanted proteins. Because RNAi can be easily tuned (in theory) to any disease, this may herald a new class of medicines.

Read More

AI startup Deep Genomics raises US$13M

October 10, 2017

The founding principle of Toronto-based Deep Genomics is “that the future of medicine will rely on artificial intelligence (AI), because biology is too complex for humans to understand.” After success at the startup assistance program run by University of Toronto’s Creative Destruction Lab, Deep Genomics has now closed a Series A financing deal that will allow it apply AI to search across 69 billion molecules to identify 1000 potential drugs.

Read More

Genetic tests to guide brain cancer treatment

September 22, 2017

Doctors at Sick Kids have developed tests to analyze the molecular makeup of individual brain tumours, leading to the possibility of personalized treatment. Hospitals from around the world are sending their patient’s tumour samples to Sick Kids for this molecular analysis.

Read More

Sun Life to look at effectiveness of pharmacogenetics on plan members

September 13, 2017

Sun Life Financial will be offering plan members on short- and long-term disability leave for depression or anxiety the chance to take part in a study on the impact of pharmacogenetic testing. The insurer is participating in a study that examines the effectiveness of the technology in partnership with the Centre for Addiction and Mental Health and personalized medicine provider Assurex Health Inc.

Read More